Last A$0.51 AUD
Change Today +0.015 / 3.03%
Volume 474.6K
As of 12:10 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

bionomics ltd (BNO) Snapshot

Open
A$0.52
Previous Close
A$0.50
Day High
A$0.52
Day Low
A$0.50
52 Week High
03/10/14 - A$0.80
52 Week Low
06/4/14 - A$0.37
Market Cap
213.0M
Average Volume 10 Days
562.8K
EPS TTM
A$0.01
Shares Outstanding
417.7M
EX-Date
--
P/E TM
44.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIONOMICS LTD (BNO)

Related News

No related news articles were found.

bionomics ltd (BNO) Related Businessweek News

No Related Businessweek News Found

bionomics ltd (BNO) Details

Bionomics Limited discovers and develops biopharmaceuticals for the treatment of cancer and disorders of the central nervous system in Australia, France, and the United States. The company develops small molecule and antibody therapeutics in the areas of cancer, anxiety, depression, and Alzheimer's disease. Its oncology approach includes cancer stem cell therapeutics, as well as vascular disruption in solid tumors. The company’s product pipeline includes BNC105, a novel compound in Phase II clinical trials to disrupt the blood vessels that nourish tumours in cancer treatment; and BNC101, a monoclonal antibody that targets cancer stem cells. It is also developing BNC210/IW-2143 for the treatment of anxiety disorders; BNC375, a small molecule therapeutic for the treatment of cognitive impairment in Alzheimers's disease; and Kv1.3 inhibitors for the treatment of inflammatory disorders. In addition, the company, through its subsidiary, Neurofit SAS, offers contract research services. It has collaboration, research, and licensing agreements with Ironwood Pharmaceuticals, Inc.; Merck & Co.; Cancer Therapeutics Cooperative Research Center; Genmab A/S; Laboratory Corporation of America; Athena Diagnostics, Inc.; and Genetic Technologies Limited. The company was founded in 1998 and is based in Thebarton, Australia.

Founded in 1998

bionomics ltd (BNO) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$407.6K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$160.8K
Chief Medical Officer
Total Annual Compensation: A$378.9K
Compensation as of Fiscal Year 2014.

bionomics ltd (BNO) Key Developments

Bionomics Ltd. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 08:00 AM

Bionomics Ltd. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 08:00 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Deborah Rathjen, Chief Executive Officer, Managing Director and Executive Director.

Bionomics Begins Phase 1b Study with Anxiety Drug BNC210

Bionomics Ltd. has initiated a Phase 1b clinical trial in healthy volunteers of BNC210, the Company's drug candidate in development for the treatment of anxiety and depression. The trial will be conducted by Biotrial International at its facility in Rennes, France and will investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BNC210. This is a randomised, double-blind, placebo-controlled trial and will treat over 50 healthy male volunteers in sequential multiple ascending doses. Four groups of subjects will be enrolled to receive one of four doses of BNC210 or placebo, twice a day for eight days. Target engagement by BNC210 will be investigated through the use of a nicotine challenge where the subjects response to nicotine will be monitored by a brain EEG. All subjects on the study will undergo a standard battery of pharmacodynamic assessments. The primary endpoint of the trial will be the safety and tolerability of BNC210 following multiple administrations with secondary endpoints investigating the pharmacokinetic and pharmacodynamic profile of BNC210 and its effect on cognitive functions and the response to nicotine. In addition a Phase 2a study for BNC210 in human patients suffering anxiety is planned with the trial anticipated to commence during first quarter of 2015 in the UK. These trials mark vital steps in the development of BNC210 and will position it for partnering opportunities.

Bionomics Ltd. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Bionomics Ltd. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BNO:AU A$0.51 AUD +0.015

BNO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BNO.
View Industry Companies
 

Industry Analysis

BNO

Industry Average

Valuation BNO Industry Range
Price/Earnings 45.2x
Price/Sales 6.6x
Price/Book 4.9x
Price/Cash Flow 45.3x
TEV/Sales 4.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIONOMICS LTD, please visit www.bionomics.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.